Sympathetically Mediated Changes in Capacitance: Redistribution of the Venous Reservoir as a Cause of Decompensation

“To be accepted as a paradigm, a theory must seem better than its competitors, but it need not, and in fact never does, explain all the facts with which it can be confronted.” Thomas Kuhn, The Structure of Scientific Revolutions ### Heard on Rounds “A 57-year-old patient with a history of heart failure states that she began experiencing worsening shortness of breath 4 days prior to admission, with lower extremity edema developing 1 day prior to admission. She is compliant with her medications, though has had similar admissions previously. She states that her weight at home increased by “a couple of pounds” 2 days ago and that she increased her diuretic dose but her symptoms worsened. She says that she generally adheres to her low salt diet, but admits to eating pretzels 5 days ago. The physical examination showed BP 136/84, HR 94, weight 3 lbs above baseline, elevated JVP, basilar rales, and 1+ pedal edema.” As the intern finishes the presentation, the Senior expresses surprise that the patient's weight had increased only 3 pounds, and comments about salt and volume overload leading to acute decompensated heart failure (ADHF). The Attending adds that recent data reveal that many patients presenting with ADHF have minimal or no weight gain, but that there is no clear mechanism to explain this phenomenon. They set in place plans for diuresis, increasing vasodilators, and further patient education. On the surface, there is nothing remarkable about this case, and the usual approaches to treat this entity have remained remarkably consistent since the advent of loop diuretics over 50 years ago: salt restriction, patient education, uptitration of medications if not already at optimal doses, and diuresis. However, approximately 1 in 4 such patients are readmitted to the hospital within 30 days,1 and the disease continues to progress. It is clear …

[1]  S. Massry,et al.  Textbook of nephrology , 2013 .

[2]  Michael Böhm,et al.  Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure: The Telemedical Interventional Monitoring in Heart Failure Study , 2011, Circulation.

[3]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[4]  D. R. Wagoner Chronic vagal nerve stimulation for the treatment of human heart failure: progress in translating a vision into reality. , 2011 .

[5]  M. Zile,et al.  Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiology. , 2011, Journal of cardiac failure.

[6]  R. Canby,et al.  Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). , 2011, Congestive heart failure.

[7]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[8]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[9]  D. V. Van Wagoner,et al.  Chronic vagal nerve stimulation for the treatment of human heart failure: progress in translating a vision into reality. , 2011, European heart journal.

[10]  D. Mann,et al.  The vagus nerve and autonomic imbalance in heart failure: past, present, and future , 2011, Heart Failure Reviews.

[11]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[12]  William T. Abraham,et al.  Physician-Directed Patient Self-Management of Left Atrial Pressure in Advanced Chronic Heart Failure , 2010, Circulation.

[13]  R. Verrier,et al.  Heart rate, autonomic markers, and cardiac mortality. , 2009, Heart rhythm.

[14]  Y. Takei,et al.  Value of the extracellular water ratio for assessment of cirrhotic patients with and without ascites , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[15]  G. Breithardt MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy): cardiac resynchronization therapy towards early management of heart failure , 2009, European heart journal.

[16]  Christopher Zimmer,et al.  Effects of tolvaptan on dyspnoea relief from the EVEREST trials. , 2009, European heart journal.

[17]  Gary S Francis,et al.  Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. , 2009, Journal of the American College of Cardiology.

[18]  G. Fink Arthur C. Corcoran Memorial Lecture. Sympathetic activity, vascular capacitance, and long-term regulation of arterial pressure. , 2009, Hypertension.

[19]  J. Sharman,et al.  Effects of bradykinin on venous capacitance in health and treated chronic heart failure , 2008, Clinical science.

[20]  E. Rackow Rehospitalizations among patients in the Medicare fee-for-service program. , 2009, The New England journal of medicine.

[21]  J. Bates,et al.  A further analysis of why pulmonary venous pressure rises after the onset of LV dysfunction. , 2009, Journal of applied physiology.

[22]  M. Zile,et al.  Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures , 2008, Circulation.

[23]  Brian Olshansky,et al.  Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. , 2008, Circulation.

[24]  S. Gelman,et al.  Venous Function and Central Venous Pressure: A Physiologic Story , 2008, Anesthesiology.

[25]  M. Zile,et al.  Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.

[26]  G. Burnstock,et al.  Sympathetic Innervation of Human Mesenteric Artery and Vein , 2008, Journal of Vascular Research.

[27]  M. Gheorghiade,et al.  Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation , 2008, European journal of heart failure.

[28]  J. Concato,et al.  Patterns of Weight Change Preceding Hospitalization for Heart Failure , 2007, Circulation.

[29]  J. McMurray,et al.  Differences in arterial compliance, microvascular function and venous capacitance between patients with heart failure and either preserved or reduced left ventricular systolic function , 2007, European journal of heart failure.

[30]  G. Fink,et al.  Splanchnic Circulation Is a Critical Neural Target in Angiotensin II Salt Hypertension in Rats , 2007, Hypertension.

[31]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[32]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[33]  K. Weber,et al.  Effect of Timed Semirecumbency and Furosemide Dosing on Urinary Sodium Excretion in Patients with Compensated Heart Failure , 2006, The American journal of the medical sciences.

[34]  Allen W. Cowley,et al.  Systems analysis of arterial pressure regulation and hypertension , 1972, Annals of Biomedical Engineering.

[35]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[36]  W. Abraham,et al.  Continuous Autonomic Assessment in Patients With Symptomatic Heart Failure: Prognostic Value of Heart Rate Variability Measured by an Implanted Cardiac Resynchronization Device , 2004, Circulation.

[37]  R. Hainsworth,et al.  Phasic negative intrathoracic pressures enhance the vascular responses to stimulation of pulmonary arterial baroreceptors in closed‐chest anaesthetized dogs , 2004, The Journal of physiology.

[38]  S. Gelman,et al.  Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. , 2004, Anesthesiology.

[39]  Robert A McNutt,et al.  Decompensated heart failure: symptoms, patterns of onset, and contributing factors. , 2003, The American journal of medicine.

[40]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[41]  D. Duprez,et al.  Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.

[42]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[43]  P. Agostoni,et al.  Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure , 2002, European journal of heart failure.

[44]  T. Nozawa,et al.  Effects of long-term renal sympathetic denervation on heart failure after myocardial infarction in rats , 2002, Heart and Vessels.

[45]  M. Frenneaux,et al.  Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. , 2001, Journal of the American College of Cardiology.

[46]  S. Goldstein,et al.  The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. , 1999, Clinical cardiology.

[47]  B. Lévy,et al.  Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: activation by angiotensin II in hypertension. , 1998, Circulation research.

[48]  G. MacGregor,et al.  How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. , 1998, Clinical science.

[49]  J. McMurray,et al.  Catecholamines contribute to exertional dyspnoea and to the ventilatory response to exercise in normal humans. , 1997, European heart journal.

[50]  J. Huidobro-Toro,et al.  Neuropeptide Y Y1 receptors are involved in the vasoconstriction caused by human sympathetic nerve stimulation. , 1997, European journal of pharmacology.

[51]  D. Sica,et al.  Treatment with enalapril fails to prevent impaired cardiopulmonary baroreflex control in dogs with left ventricular dysfunction. , 1995, Journal of cardiac failure.

[52]  M. Dibner-dunlap,et al.  Altered vagal and sympathetic control of heart rate in left ventricular dysfunction and heart failure. , 1995, The American journal of physiology.

[53]  D. Burkhoff,et al.  Why does pulmonary venous pressure rise after onset of LV dysfunction: a theoretical analysis. , 1993, The American journal of physiology.

[54]  M. Thames,et al.  Abnormalities of baroreflex control in heart failure. , 1993, Journal of the American College of Cardiology.

[55]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[56]  C. Rothe,et al.  Mean circulatory filling pressure: its meaning and measurement. , 1993, Journal of applied physiology.

[57]  M. Thames,et al.  Control of Sympathetic Nerve Activity by Vagal Mechanoreflexes Is Blunted in Heart Failure , 1992, Circulation.

[58]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[59]  P. Schwartz,et al.  Sympathetic-parasympathetic interaction and accentuated antagonism in conscious dogs. , 1991, The American journal of physiology.

[60]  ON BEDRESTING IN HEART FAILURE , 1990, The Lancet.

[61]  D L Eckberg,et al.  Autonomic pathophysiology in heart failure: carotid baroreceptor-cardiac reflexes. , 1990, The American journal of physiology.

[62]  U. Dahlström,et al.  Neuroendocrine response in acute heart failure and the influence of treatment. , 1989, European heart journal.

[63]  M. Thames,et al.  Baroreflex Control of Renal Sympathetic Nerve Activity Is Preserved in Heart Failure Despite Reduced Arterial Baroreceptor Sensitivity , 1989, Circulation research.

[64]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[65]  J. Firth,et al.  RAISED VENOUS PRESSURE: A DIRECT CAUSE OF RENAL SODIUM RETENTION IN OEDEMA? , 1988, The Lancet.

[66]  D. Karnad,et al.  Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. , 1986, British medical journal.

[67]  R. Hainsworth,et al.  Vascular capacitance: its control and importance. , 1986, Reviews of physiology, biochemistry and pharmacology.

[68]  N. Christensen,et al.  Bed rest and increased diuretic treatment in chronic congestive heart failure. , 1985, European heart journal.

[69]  M. Packer,et al.  Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. , 1985, Circulation.

[70]  W. Ammons,et al.  Neural and vascular interaction in renin response to graded renal nerve stimulation. , 1982, The American journal of physiology.

[71]  F. Ingelfinger,et al.  The effect of the upright posture upon hepatic blood flow in normotensive and hypertensive subjects. , 1951, The Journal of clinical investigation.